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Background: HMG-CoA reductase inhibitors (statins) have pleiotropic effects that are independent of
cholesterol-lowering, including a dose-dependent effect on angiogenesis. Angiogenesis plays a critical role both
in vascularization of the chronically ischemic myocardium and in stabilization of atherosclerotic plaques.
Chemokines, a family of structurally-related cytokine molecules, exert diverse biological functions including control
of angiogenesis. The effect of statin therapy on angiogenic and angiostatic chemokines has not been evaluated
extensively. We sought to test the hypothesis that, in subjects with hyperlipidemia, statin therapy influences plasma
levels of angiogenic and angiostatic chemokines in a dose-dependent manner.
Methods: We prospectively collected demographic, angiographic and laboratory data from subjects with a history
of hyperlipidemia who were either untreated or on statin therapy. A peripheral blood sample was obtained for
measurement of plasma angiogenic and angiostatic chemokines. Multivariable analysis using logistic regression was
performed adjusting for the following variables: age, gender, prior myocardial infarction, and chronic administration
of aspirin, clopidogrel, insulin, oral hypoglycemic agents, beta-blockers and calcium channel blockers.
Results: 168 patients on statin therapy (48 on low-dose, defined as <10mg atorvastatin-equivalent, and 120 on
high-dose, defined as ≥10mg atorvastatin-equivalent dose) and 11 subjects from the same database who had a
history of hyperlipidemia but who were not on statins were enrolled. There were no significant differences in
baseline demographics, co-morbidities, lipid panels, other medications, or angiographic data between the groups.
The angiogenic chemokines CXCL1 and CXCL12 levels were significantly different across the groups. Median levels
of CXCL1 were highest in subjects not on statin therapy. Compared to subjects either not on statin therapy or on
low-dose statins, those taking high-dose statins had lower median values of CXCL12 (2316 [2255–11071], vs 2362
[2016–10622], vs 2189 [1968–2705] pg/mL, p=0.042). On multivariate analysis, CXCL12 remained the only factor that
was strongly and inversely associated with statin dose at the 95% level (p=0.011).
Conclusions: Compared to no therapy or low-dose statin therapy, treatment with high-doses of HMG-CoA
reductase inhibitors is associated with decreased circulating CXCL12 levels in subjects with hyperlipidemia, and
CXCL12 is strongly and inversely associated with statin dose. Additional studies are needed to confirm this finding
in other cohorts and to determine if high-dose statins affect angiogenesis in patients.
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HMG-CoA reductase inhibitors are among the most
commonly prescribed medications, and have pleiotropic
effects that are independent of cholesterol-lowering [1].
Among these, several lines of evidence support a dose-
dependent effect of these drugs on angiogenesis; for
example, in animal models, inflammation-induced angio-
genesis is enhanced with low-dose statin therapy but
inhibited at high statin concentrations, and high-dose
statin concentration is associated with decreased tumor
vascularization in a lung cancer model [2]. Moreover,
in vitro studies demonstrate that low-dose statin concen-
trations are pro-angiogenic by promoting the migration
of human endothelial progenitor cells while at high con-
centrations they are anti-angiogenic by promoting endo-
thelial cell apoptosis [3]. The effects of statins on
angiogenesis in humans are likely to be clinically relevant
to heart disease since angiogenesis is associated with for-
mation of new blood vessels in chronically ischemic myo-
cardium; in addition, inhibition of angiogenesis may
contribute to stabilization of atherosclerotic plaques [4].
Chemokines are a family of structurally-related cyto-
kine molecules with diverse biological functions, includ-
ing control of angiogenesis. We recently reported that,
in subjects with coronary artery disease, the plasma con-
centration of angiogenic chemokines was independently
associated with the presence and extent of angiographi-
cally visible coronary collaterals, whereas the concentra-
tion of angiostatic chemokines was negatively correlated
[5]. The effect of statin therapy on angiogenic and angio-
static chemokines in subjects with coronary artery dis-
ease has not been evaluated extensively. Given the high
prevalence of statin use in the population, we sought to
test the hypothesis that, in subjects with hyperlipidemia,
statin therapy influences plasma levels of angiogenic and
angiostatic chemokines in a dose-dependent manner.
Methods
Patient population
We prospectively collected demographic, angiographic
and laboratory data from consecutive subjects with a his-
tory of hyperlipidemia undergoing elective coronary angi-
ography at the University of Virginia from October 2007
to August 2008. The study was approved by the Institu-
tional Review Board and all subjects provided informed
consent. Patients > 21 years old who were able to provide
informed consent were eligible for enrollment. Exclusion
criteria were: (1) acute coronary syndrome, (2) active in-
flammatory, infectious, or malignant disease, and (3) im-
munosuppressive therapy. Doses of statins were converted
to an atoravastatin-equivalent on the basis of their low-
density lipoprotein-lowering potential as previously
described [6]. Subjects were classified as not on a statin,
on low-dose statins (defined as <10mg atorvastatin-equivalent dose which included the following: lovastatin
10mg and 20mg; pravastatin 10mg and 20mg; and simvas-
tatin 5mg and 10mg) or on high-dose statins (defined as
≥10mg atorvastatin-equivalent dose which included the
following: atorvastatin 10mg, 20mg, 40mg and 80mg;
lovastatin 40mg and 80mg; pravastatin 40mg and 80mg;
rosuvastatin 5mg, 10mg, 20mg and 40mg; and simvastatin
20mg, 40mg and 80mg) [6].
Blood sampling and cytokine analysis
At the time of arterial sheath insertion for coronary
angiography and prior to administration of heparin, a
blood sample was drawn from the side arm of the sheath
and anticoagulated with sodium EDTA, placed on ice,
and processed within 30 minutes of retrieval. Platelet-
free plasma was aliquoted and frozen at −80°C for
subsequent measurement of cytokines by multiplex
immunoassay (Luminex, Bio-Rad, Bio-plex 200 system,
Hercules, California; Procarta Cytokine Assay kit,
Panomics, Inc., Fremont, California). We assayed for the
angiogenic chemokines CXCL1, CXCL3, CXCL5,
CXCL8, CXCL12 and CCL2, the angiogenic cytokine
VEGF, the angiostatic chemokines CXCL9, CXCL10 and
CXCL11, and the cytokine interferon-gamma (a potent
inducer of angiostatic chemokines).
Statistical analysis
Baseline characteristics were analyzed using Wilcoxon
rank-sum test for continuous and Chi-Square test or
Fisher’s Exact test for categorical variables. Statistically
significant differences between groups were compared
with one-way analysis of variance (ANOVA). Multivari-
able analysis using logistic regression was performed
adjusting for the following variables: age, gender, prior
myocardial infarction, and chronic administration of as-
pirin, clopidogrel, insulin, oral hypoglycemic agents,
beta-blockers and calcium channel blockers. Analyses
were performed using Stata/ IC version 10.1 (Statacorp)
and GraphPad PRISM (version 5.0d). Statistical signifi-
cance was defined as p value of <0.05.
Results
A total of 168 subjects with a history of hyperlipidemia
on chronic statin therapy (low-dose n=48, and high-dose
n=120), and 11 subjects with a history of hyperlipidemia
not on lipid-lowering therapy were enrolled. There were
no significant differences in baseline medications, fasting
lipid levels, medical co-morbidities, the presence of cor-
onary artery disease, and the presence of angiographic
coronary collaterals between the groups (Table 1). Over-
all, few subjects had a clinical history of congestive heart
failure and there was no difference in its prevalence be-
tween the groups: echocardiographic assessment of left
ventricular systolic function revealed that both subjects
Table 1 Characteristics of Subjects
Characteristic No statin(n=11) Low dose statin(n=48) High dose statin (n=120) p Value
Age (years) 65 +/- 14 64 +/- 11 60 +/- 12 0.489
Male gender 8 (73%) 31 (65%) 85 (71%) 0.707
Race
Caucasian 11 (100%) 41 (85%) 106 (88%) 0.398
African-American 0 (0%) 7 (15%) 14 (12%) 0.398
Hypertension* 7 (64%) 42 (88%) 104 (87%) 0.098
Diabetes mellitus 4 (36%) 11 (23%) 39 (33%) 0.874
Tobacco use 4 (36%) 10 (21%) 33 (28%) 0.730
Family history of CAD 2 (18%) 23 (48%) 51 (43%) 0.047
Prior Angina 5 (45%) 17 (35%) 55 (46%) 0.802
Peripheral arterial disease 1 (9%) 10 (21%) 33 (28%) 0.460
Congestive heart failure 2 (18%) 3 (6%) 9 (8%) 0.958
Myocardial infarction 3 (27%) 11 (23%) 48 (40%) 0.050
Prior CABG 3 (27%) 4 (8%) 22 (18%) 0.104
Prior PCI 3 (27%) 16 (33%) 47 (40%) 0.401
Prior Stroke 0 (0%) 3 (6%) 18 (15%) 0.445
Medications
Beta-blocker 7 (64%) 27 (56%) 84 (71%) 0.183
ACE inhibitor 3 (27%) 22 (46%) 53 (45%) 0.397
Aspirin 9 (82%) 36 (75%) 102 (86%) 0.678
Insulin 2 (18%) 5 (10%) 13 (11%) 0.652
Oral hypoglycemic 1 (9%) 7 (15%) 16 (14%) 0.869
Calcium channel blocker 2 (18%) 10 (21%) 15 (13%) 0.681
Clopidogrel 4 (36%) 11 (23%) 30 (25%) 0.393
Lipid panel (mmol/L)
Total cholesterol 160 [134-161] 157 [136-177] 161 [135-200] 0.593
Low density lipoprotein 88 [81-106] 95 [80-112] 92 [74-131] 0.815
High density lipoprotein 43 [37-51] 38 [33-47] 38 [32-44] 0.128
Triglycerides 89 [55-131] 111 [85-199] 132 [100-194] 0.098
Angiographic data
Obstructive CAD † 10 (91%) 39 (81%) 106 (88%) 0.434
Non-obstructive CAD 1 (9%) 8 (17%) 19 (16%) 0.819
Presence of collaterals 3 (27%) 16 (67%) 42 (60%) 0.868
Cytokines (pg/mL)
CXCL1 10516 [2094-27454] 4087 [899-18355] 7709 [1749-20804] 0.026
CXCL3 987 [288-1351] 514 [230-1163] 632 [215-1003] 0.359
CXCL5 5820 [4041-15103] 5127 [2326-8607] 5820 [2985-9245] 0.290
CXCL8 741 [517-1391] 751 [367-1441] 758 [345-1664] 0.884
CXCL9 4133 [68-16835] 3421 [297-7749] 3558 [392-7741] 0.890
CXCL10 1552 [922-2075] 922 [587-1362] 901 [587-1670] 0.117
CXCL11 7577 [2920-9914] 5072 [2711-7724] 4449 [2786-7500] 0.259
CXCL12 2316 [2255-11071] 2362 [2016-10622] 2189 [1968-2705] 0.042
CCL2 131 [32-163] 58 [39-92] 62 [28-132] 0.259
VEGF 909 [559-3997] 1219 [205-1991] 957 [147-1880] 0.678
IFN-γ 472 [92-1034] 317 [113-472] 304 [147-525] 0.467
Data are expressed as mean ± standard deviation (SD), median [25-75% interquartile range (IQR)], or as number (percentage), ACE= angiotensin
converting-enzyme, CABG= coronary artery bypass graft surgery, CAD= coronary artery disease, IFN= interferon, PCI= percutaneous coronary intervention,
VEGF= vascular endothelial growth factor *= on antihypertensive medications, or untreated patients with known systolic blood pressure ≥140mmHg or diastolic
blood pressure ≥90mmHg †= ≥70% luminal diameter narrowing of at least one major epicardial artery.
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(defined as 45-50%), 2 subjects in the low-dose group
had mildy depressed and 1 had moderately depressed
(defined as 40-45%) function, and in the high-dose
group, 5 had mildly depressed and 4 had moderately
depressed function. Subjects taking statins had higher
rates of a family history of coronary artery disease
(p=0.047) (Table 1).
While the angiogenic chemokines, CXCL1 and CXCL12,
were significantly different across the groups, there were no
differences in median levels of angiostatic chemokines,
VEGF or interferon-gamma. Median levels of CXCL1 were
highest in subjects not on statin therapy. Compared to sub-
jects either not on statin therapy or on low-dose statins,
those taking high-dose statins had lower median values of
CXCL12 (2316 [2255–11071], vs 2362 [2016–10622], vs
2189 [1968–2705] pg/mL, p=0.042). CXCL12 levels in
those not on statin therapy were similar to those on low-
dose statin (2316 [2255–11071] vs 2362 [2016–10622] pg/
mL, respectively, p=0.181), suggesting that low-dose statins
do not increase CXCL12 levels but rather high-dose statins
decrease CXCL12 levels. On multivariate analysis, after
adjusting for age, gender, prior myocardial infarction, and
chronic administration of aspirin, clopidogrel, insulin, oral
hypoglycemic agents, beta-blockers and calcium channel
blockers, CXCL12 remained the only factor that was
strongly and inversely associated with statin dose at the
95% level (p=0.011). While all subjects had been on statin
therapy for at least 2 weeks prior to coronary angiography
the duration of statin therapy beyond 2 weeks was not
known in all subjects. In the 81 subjects in whom the dur-
ation beyond 2 weeks was known, however, there was no
difference in the median number of weeks of statin therapy
between those on low-dose versus high-dose statin (48
[21–108] vs 49 [25–88], p=0.832).
Discussion
The effect of statins on angiogenesis is dose-dependent
and independent of lipid lowering [2,3]. At low doses, sta-
tins promote angiogenesis by enhancing endothelial cell
proliferation, migration and differentiation, while at high
doses they exert anti-angiogenic effects by inducing endo-
thelial cell apoptosis [2,3]. In addition, statins promote the
trafficking of bone marrow-derived progenitor cells into
atherosclerotic plaque [7]. In patients with coronary artery
disease, statins have been associated with down-regulation
of several chemokine ligands [8], but their potential effect
on CXCL12, a potent mediator of angiogenesis, has not
been reported previously.
CXCL12 plays a unique role in angiogenesis. CXCL12 is
constitutively expressed in the bone marrow, and periph-
eral tissues including the heart, and mediates angiogenesis
by regulating the trafficking of endothelial progenitor cells
[9]. In a mouse model of pulmonary hypertension,administration of pravastatin ameliorated hypoxia-
induced pulmonary hypertension and was associated with
decreased accumulation of bone marrow-derived progeni-
tor cells in the pulmonary artery adventitia and reduced
plasma levels of CXCL12 [10]. In a hind-limb ischemia
model, investigators determined the effects of fluvastatin
and CXCL12 on angiogenesis [11]. They found that treat-
ment with fluvastatin and CXCL12 together additively
increased migration and proliferation of endothelial pro-
genitor cells into the ischemic issue, improved reperfu-
sion, and down-regulated apoptosis more effectively than
treatment with either agent alone [11]. Whether statins
play a role in the progression of atherosclerosis was exam-
ined in a separate study where apolipoprotein E knockout
mice on an atherogenic diet were treated with rosuvastatin
(1mg and 10mg/kg of body weight) or pravastatin (10mg/
kg of body weight) [7]. They found that treatment with
rosuvastatin (particularly in those treated with a high dos-
age of the statin), but not pravastatin, dose-dependently-
reduced the size of atherosclerotic plaques [7]. Moreover,
compared to control-treated animals, the plaques in
statin-treated animals were characterized by a higher de-
gree of endothelialization and increased numbers of bone
marrow-derived progenitor cells within the lesions [7].
Our finding that the angiogenic chemokine CXCL1 was
significantly higher in a small number of subjects not on
statin therapy is consistent with a previously published
paper where investigators found that in 8 subjects with
coronary artery disease who were not on statin therapy at
baseline, 6 months of high-dose atorvastatin treatment
(80mg daily) was associated with a significant decrease in
the gene expression of CXCL1 in their peripheral blood
mononuclear cells [12]. Lastly, the heterogeneity in blood
levels of CXCL12 is consistent with that of other chemo-
kines and has been noted before [5,13]. Our data suggests
that statin dose is important and may shed light on the
mechanism by which statins exert a biphasic effect on
angiogenesis. We show that plasma CXCL12 levels in
patients on statin therapy were strongly and inversely
associated with statin dose. This finding maybe clinically
important in that high doses of statins may inhibit neovas-
cularization in humans which could manifest as
stabilization of vulnerable atherosclerotic plaques by sup-
pressing angiogenesis within the plaque, or by inhibiting
neovascularization within the ischemic myocardium.
Thus, additional human studies with larger numbers of
participants are needed to define the effect of statin
dose on angiogenesis directly.
Our study has limitations. First, although all subjects
were on chronic statin therapy for at least 2 weeks, the
duration of statin therapy prior to 2 weeks was not avail-
able for all patients. However, in those in whom the dur-
ation was known, there was no difference in median
number of weeks of statin therapy prior to coronary
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Second, the small sample size may have limited our abil-
ity to find other differences between the groups. Third,
we may have underestimated the extent of collaterals by
measuring only spontaneously visible coronary collat-
erals. Fourth, we did not measure peripheral blood
endothelial progenitor cells which may be impacted by
CXCL12 levels. Lastly, our results reflect an association
but do not establish a causal relationship between statin
dose and CXCL12 levels.
Conclusions
Compared to no therapy or low-dose statin therapy, treat-
ment with high-doses of HMG-CoA reductase inhibitors is
associated with decreased circulating CXCL12 levels in
subjects with hyperlipidemia, and CXCL12 is strongly and
inversely associated with statin dose. Additional studies are
needed to confirm this finding in other cohorts and to de-
termine if high-dose statins affect angiogenesis in patients.
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